{"id":"tolvaptan-or-samsca","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL344159","moleculeType":"Small molecule","molecularWeight":"448.95"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking the V2 receptor, tolvaptan reduces water reabsorption in the kidneys, leading to increased urine production and decreased fluid volume in the body. This mechanism is particularly useful in treating conditions such as hyponatremia and heart failure.","oneSentence":"Tolvaptan is a selective, competitive antagonist of the vasopressin V2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:16.681Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hyponatremia"},{"name":"Autonomic dysfunction in heart failure"}]},"trialDetails":[{"nctId":"NCT04782258","phase":"PHASE3","title":"A Study to See Iftolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old withAutosomal Recessive Polycystic Kidney Disease (ARPKD)","status":"RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2023-01-23","conditions":"Autosomal Recessive Polycystic Kidney (ARPKD)","enrollment":20},{"nctId":"NCT05190744","phase":"PHASE2","title":"Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2022-09-01","conditions":"Autosomal Dominant Polycystic Kidney Disease, Nephrogenic Diabetes Insipidus, Acquired Nephrogenic Diabetes Insipidus","enrollment":36},{"nctId":"NCT02925221","phase":"","title":"Canadian Medical Assessment of JINARC™ Outcomes Registry","status":"COMPLETED","sponsor":"Otsuka Canada Pharmaceutical Inc.","startDate":"2016-02-26","conditions":"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","enrollment":530},{"nctId":"NCT04786574","phase":"PHASE3","title":"A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)","status":"WITHDRAWN","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-07-01","conditions":"Autosomal Recessive Polycystic Kidney Disease (ARPKD)","enrollment":""},{"nctId":"NCT00664014","phase":"PHASE2","title":"A Phase 2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2008-05","conditions":"Hypovolemic Hyponatremia","enrollment":241},{"nctId":"NCT05712746","phase":"","title":"Samtasu Post-marketing General Drug Use-results Survey in Patients with Volume Overload in Heart Failure.","status":"RECRUITING","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2023-03-03","conditions":"Heart Failure","enrollment":1600},{"nctId":"NCT02497521","phase":"","title":"The German ADPKD Tolvaptan Treatment Registry","status":"RECRUITING","sponsor":"University of Cologne","startDate":"2015-11","conditions":"ADPKD (Autosomal Dominant Polycystic Kidney Disease)","enrollment":2000},{"nctId":"NCT03255226","phase":"PHASE3","title":"Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Tolvaptan in Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2018-03-07","conditions":"Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload","enrollment":60},{"nctId":"NCT06171100","phase":"","title":"Low-dose Tolvaptan for Inpatient Hyponatraemia.","status":"RECRUITING","sponsor":"King's College Hospital NHS Trust","startDate":"2024-03-15","conditions":"Hyponatremia, SIADH","enrollment":180},{"nctId":"NCT03541447","phase":"PHASE2","title":"Tolvaptan-Octreotide LAR Combination in ADPKD","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2018-12-12","conditions":"Autosomal Dominant Polycystic Kidney Disease","enrollment":20},{"nctId":"NCT01214421","phase":"PHASE3","title":"Tolvaptan Extension Study in Participants With ADPKD","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-05-26","conditions":"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","enrollment":1083},{"nctId":"NCT01684202","phase":"PHASE2","title":"A Multicenter, Open-label, Dose-finding Trial of OPC-41061 to Investigate Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety in Patients With Carcinomatous Edema (Phase 2)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2012-07","conditions":"Carcinomatous Edema","enrollment":43},{"nctId":"NCT03048747","phase":"PHASE3","title":"A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2017-03-02","conditions":"Syndrome of Inappropriate Antidiuretic Hormone Secretion","enrollment":16},{"nctId":"NCT02959411","phase":"PHASE4","title":"Tolvaptan for Advanced or Refractory Heart Failure","status":"TERMINATED","sponsor":"University of Calgary","startDate":"2016-10","conditions":"Heart Failure, Hyponatremia","enrollment":9},{"nctId":"NCT02020278","phase":"PHASE3","title":"An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Participants With Euvolemic or Hypervolemic Hyponatremia","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2016-04-22","conditions":"Hyponatremia","enrollment":3},{"nctId":"NCT02251275","phase":"PHASE3","title":"Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2014-10-17","conditions":"Polycystic Kidney, Autosomal Dominant","enrollment":1803},{"nctId":"NCT02606253","phase":"PHASE4","title":"Comparison of Oral or Intravenous Thiazides vs Tolvaptan in Diuretic Resistant Decompensated Heart Failure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2016-02","conditions":"Heart Failure","enrollment":60},{"nctId":"NCT02331680","phase":"PHASE2","title":"A Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2014-12","conditions":"Chronic Renal Failure","enrollment":124},{"nctId":"NCT04119206","phase":"","title":"Tolvaptan Versus Fluid Restriction in SIADH","status":"COMPLETED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2009-01-01","conditions":"Hyponatremia, Syndrome of Inappropriate ADH (SIADH) Secretion, Pituitary","enrollment":334},{"nctId":"NCT02183792","phase":"PHASE4","title":"Aquaresis Utility for Hyponatremic Acute Heart Failure Study","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2014-12","conditions":"Heart Failure","enrollment":33},{"nctId":"NCT01280721","phase":"PHASE3","title":"A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2010-11","conditions":"Autosomal Dominant Polycystic Kidney Disease （ADPKD)","enrollment":135},{"nctId":"NCT02012959","phase":"PHASE3","title":"Study of the Safety and Effectiveness of SAMSCA® (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic Hyponatremia","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2015-09-22","conditions":"Hyponatremia","enrollment":9},{"nctId":"NCT01876381","phase":"PHASE2","title":"A Phase 2, Multi-center, Open-label, Dose-finding Trial to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of OPC-41061 in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2013-06","conditions":"Chronic Renal Failure","enrollment":26},{"nctId":"NCT02666651","phase":"PHASE4","title":"Regional Tolvaptan Registry","status":"UNKNOWN","sponsor":"Cardiology Research UBC","startDate":"2016-05","conditions":"Decompensated Heart Failure, Hyponatremia","enrollment":25},{"nctId":"NCT02160145","phase":"PHASE3","title":"Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2014-05","conditions":"Chronic Kidney Disease, Autosomal Dominant Polycystic Kidney Disease","enrollment":1370},{"nctId":"NCT02173288","phase":"PHASE2, PHASE3","title":"Role of Midodrine and Tolvaptan in Patients With Cirrhosis With Refractory or Recurrent Ascites","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2013-07","conditions":"Cirrhosis, Refractory/Recurrent Ascites","enrollment":50},{"nctId":"NCT02442674","phase":"PHASE3","title":"A Trial of Tolvaptan in Children and Adolescent Subjects With Euvolemic and Hypervolemic Hyponatremia","status":"WITHDRAWN","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2015-11","conditions":"Hyponatremia","enrollment":""},{"nctId":"NCT00413777","phase":"PHASE2","title":"Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2005-12","conditions":"Polycystic Kidney, Autosomal Dominant","enrollment":46},{"nctId":"NCT00428948","phase":"PHASE3","title":"Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2007-01","conditions":"Polycystic Kidney Disease, Autosomal Dominant","enrollment":1445},{"nctId":"NCT01644331","phase":"PHASE3","title":"Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure","status":"COMPLETED","sponsor":"Duke University","startDate":"2012-10","conditions":"Heart Failure, Dyspnea","enrollment":257},{"nctId":"NCT01386372","phase":"PHASE2","title":"Tolvaptan for In-hospital Hyponatremia","status":"TERMINATED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2011-06","conditions":"Hyponatremia","enrollment":3},{"nctId":"NCT01973140","phase":"PHASE4","title":"Effects of Tolvaptan in Healthy Adults","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2013-11","conditions":"Healthy","enrollment":17},{"nctId":"NCT01584557","phase":"PHASE3","title":"Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management","status":"COMPLETED","sponsor":"Cardiovascular Clinical Sciences Inc","startDate":"2012-06","conditions":"Heart Failure","enrollment":250},{"nctId":"NCT02009878","phase":"PHASE1, PHASE2","title":"A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2013-11","conditions":"Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)","enrollment":30},{"nctId":"NCT01048788","phase":"PHASE3","title":"A Trial of OPC-41061 in Patients With Hepatic Edema - Investigation of the Safety of Treatment at 7.5 mg Beyond 7 Days and of the Effect of Dose Escalation to 15 mg","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2009-12","conditions":"Cirrhosis","enrollment":51},{"nctId":"NCT01863511","phase":"PHASE4","title":"Tolvaptan/Ultrafiltration in the Treatment of Acute Heart Failure","status":"COMPLETED","sponsor":"The Christ Hospital","startDate":"2013-05","conditions":"Acute Decompensated Heart Failure","enrollment":45},{"nctId":"NCT02449044","phase":"PHASE3","title":"International, Multicenter, Study of One-year, Open-label, Titrated Oral Tolvaptan Tablet Administration in Patients With Chronic Hyponatremia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2004-05","conditions":"Hyponatremia","enrollment":111},{"nctId":"NCT01227512","phase":"PHASE3","title":"Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-10","conditions":"Hyponatremia, Dilutional Hyponatremia, Inappropriate ADH Syndrome","enrollment":124},{"nctId":"NCT00525265","phase":"PHASE3","title":"A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2007-09","conditions":"Cardiac Edema","enrollment":20},{"nctId":"NCT01716611","phase":"PHASE4","title":"Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites","status":"UNKNOWN","sponsor":"Konkuk University Medical Center","startDate":"2012-11","conditions":"Hyponatremia, Ascites","enrollment":105},{"nctId":"NCT01507727","phase":"PHASE2, PHASE3","title":"Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2012-01","conditions":"Non-hypovolemic Non-acute Hyponatremia","enrollment":240},{"nctId":"NCT00550459","phase":"PHASE3","title":"Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2007-08","conditions":"Hyponatremia","enrollment":57},{"nctId":"NCT01014416","phase":"PHASE1","title":"Pharmacokinetics/Pharmacodynamics (PK/PD) Characteristics of Tolvaptan Tablet in Korean Healthy Male","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2010-01","conditions":"Healthy","enrollment":46}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1769,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Tolvaptan or Samsca","genericName":"Tolvaptan or Samsca","companyName":"Cardiovascular Clinical Sciences Inc","companyId":"cardiovascular-clinical-sciences-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tolvaptan, also known as Samsca, is a small molecule that acts as a vasopressin V2 receptor antagonist. It is used to treat conditions such as hyponatremia, SIADH, heart failure, non-hypovolemic non-acute hyponatremia, and chronic renal failure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}